Literature DB >> 18837947

Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps.

Ying-Hsiu Su1, Mengjun Wang, Dean E Brenner, Pamela A Norton, Timothy M Block.   

Abstract

Our previous studies demonstrated that urine contains DNA derived from the circulation and that this DNA originated, in part, from organ sites and tumors distal to the urinary tract. To explore the potential use of DNA from urine as compared to other body fluids as a source for circulating DNA for cancer detection, the DNA concentration and the frequency of detection of mutated Kristin-ras (K-ras) DNA in serum, plasma, and urine were examined. The concentration of DNA in the urine was similar to that in the serum, but the DNA concentration in plasma was significantly lower than in either urine or serum (P < 0.05). When DNA derived from 10 muL of body fluid was used in each mutation assay, the detection frequency of mutated K-ras DNA was comparable among serum, plasma, and urine. However, when DNA derived from 200 muL of body fluid was used, the incidence of detecting mutated K-ras DNA in urine was significant higher (95%) than in either serum (35%) or plasma (40%) (P < 0.0005), suggesting that inhibitory factors in serum/plasma may be more limiting than in urine. The use and practicality of urine as a source of circulating DNA for cancer detection are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18837947      PMCID: PMC2587049          DOI: 10.1196/annals.1448.027

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  43 in total

1.  Transrenal DNA as a diagnostic tool: important technical notes.

Authors:  Ying-Hsiu Su; Mengjun Wang; Timothy M Block; Olfert Landt; Irina Botezatu; Ol'ga Serdyuk; Anatoly Lichtenstein; Hovsep Melkonyan; L David Tomei; Samuil Umansky
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

2.  Molecular detection of prostate cancer in urine by GSTP1 hypermethylation.

Authors:  P Cairns; M Esteller; J G Herman; M Schoenberg; C Jeronimo; M Sanchez-Cespedes; N H Chow; M Grasso; L Wu; W B Westra; D Sidransky
Journal:  Clin Cancer Res       Date:  2001-09       Impact factor: 12.531

3.  Strategies for detection of transfusion-transmitted viruses eluding identification by conventional serologic tests. II. Detection of host DNA in human plasmas with elevated alanine aminotransferase.

Authors:  A R Neurath; N Strick; K Miller; A A Waldman
Journal:  J Virol Methods       Date:  1984-02       Impact factor: 2.014

4.  Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer.

Authors:  Eirini Papadopoulou; Elias Davilas; Vasilios Sotiriou; Alexander Koliopanos; Filipos Aggelakis; Konstantinos Dardoufas; Niki J Agnanti; Irini Karydas; Georgios Nasioulas
Journal:  Oncol Res       Date:  2004       Impact factor: 5.574

5.  Circulating DNA in polyarteritis nodosa and related syndromes.

Authors:  C R Steinman
Journal:  Arthritis Rheum       Date:  1982-12

6.  Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy.

Authors:  Hans Jörg Hacker; Wei Zhang; Mehmet Tokus; Thomas Bock; Claus H Schröder
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

7.  Free DNA in the serum of cancer patients and the effect of therapy.

Authors:  S A Leon; B Shapiro; D M Sklaroff; M J Yaros
Journal:  Cancer Res       Date:  1977-03       Impact factor: 12.701

8.  The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythematosus and other diseases.

Authors:  D Koffler; V Agnello; R Winchester; H G Kunkel
Journal:  J Clin Invest       Date:  1973-01       Impact factor: 14.808

9.  Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease.

Authors:  B Shapiro; M Chakrabarty; E M Cohn; S A Leon
Journal:  Cancer       Date:  1983-06-01       Impact factor: 6.860

10.  Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients.

Authors:  Paul Cairns
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 6.499

View more
  36 in total

Review 1.  Detection of human papillomavirus DNA in urine. A review of the literature.

Authors:  A Vorsters; I Micalessi; J Bilcke; M Ieven; J Bogers; P Van Damme
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-08-05       Impact factor: 3.267

2.  Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma.

Authors:  Hiroyuki Terasawa; Hideaki Kinugasa; Soichiro Ako; Mami Hirai; Hiroshi Matsushita; Daisuke Uchida; Takeshi Tomoda; Kazuyuki Matsumoto; Shigeru Horiguchi; Hironari Kato; Kazuhiro Nouso; Hiroyuki Okada
Journal:  Cancer Biol Ther       Date:  2019-07-22       Impact factor: 4.742

3.  New method to preserve the original proportion and integrity of urinary cell-free DNA.

Authors:  Pei Li; Jun Ning; Xipeng Luo; Hongli Du; Qing Zhang; Ganlin Zhou; Qiu Du; Zhenyu Ou; Long Wang; Yu Wang
Journal:  J Clin Lab Anal       Date:  2018-09-02       Impact factor: 2.352

4.  A locked nucleic acid clamp-mediated PCR assay for detection of a p53 codon 249 hotspot mutation in urine.

Authors:  Selena Y Lin; Veerpal Dhillon; Surbhi Jain; Ting-Tsung Chang; Chi-Tan Hu; Yih-Jyh Lin; Shun-Hua Chen; Kung-Chao Chang; Wei Song; Lixin Yu; Timothy M Block; Ying-Hsiu Su
Journal:  J Mol Diagn       Date:  2011-07-02       Impact factor: 5.568

5.  Mass spectrometric based analysis, characterization and applications of circulating cell free DNA isolated from human body fluids.

Authors:  Vaneet K Sharma; Paul Vouros; James Glick
Journal:  Int J Mass Spectrom       Date:  2011-07       Impact factor: 1.986

Review 6.  Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.

Authors:  Chien-Chung Lin; Wei-Lun Huang; Fang Wei; Wu-Chou Su; David T Wong
Journal:  Expert Rev Mol Diagn       Date:  2015-09-30       Impact factor: 5.225

7.  Differential methylation of the promoter and first exon of the RASSF1A gene in hepatocarcinogenesis.

Authors:  Surbhi Jain; Lijia Xie; Batbold Boldbaatar; Selena Y Lin; James P Hamilton; Stephen J Meltzer; Shun-Hua Chen; Chi-Tan Hu; Timothy M Block; Wei Song; Ying-Hsiu Su
Journal:  Hepatol Res       Date:  2014-12-09       Impact factor: 4.288

Review 8.  Clinical applications of urinary cell-free DNA in cancer: current insights and promising future.

Authors:  Tian Lu; Jinming Li
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

9.  Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods.

Authors:  Takuya Araki; Kimihiro Shimizu; Katsunori Nakamura; Tomonori Nakamura; Yasumasa Mitani; Kyoko Obayashi; Yukiyoshi Fujita; Seiichi Kakegawa; Yohei Miyamae; Kyoichi Kaira; Takefumi Ishidao; Alexander Lezhava; Yoshihide Hayashizaki; Izumi Takeyoshi; Koujirou Yamamoto
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

10.  Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs.

Authors:  S Chen; J Zhao; L Cui; Y Liu
Journal:  Clin Transl Oncol       Date:  2016-07-28       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.